$BCTX News

BriaCell Therapeutics Announces Pricing of Offering

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License